ENNOV acquired by BREGAL SAGEMOUNT & ARDIAN

Ennov functions as a mission-critical infrastructure software provider tailored for the life sciences and healthcare ecosystems, which are defined by rigorous, ever-evolving compliance mandates enforced by global regulatory bodies like the FDA and the EMA. The target’s competitive positioning relies on replacing fragmented, legacy point solutions with a unified software platform that centralizes highly sensitive workflows, including regulatory affairs, pharmacovigilance, clinical trials, and quality management. The business model is driven by a predictable SaaS and cloud subscription revenue architecture sold to a global pharmaceutical and biotechnology customer base. Given the deeply embedded nature of regulatory systems in life sciences workflows, the target benefits from exceptionally high customer switching costs, driving strong net retention rates and long-term cash flow visibility. The primary value driver resides in the integration of data and content management onto a single database, which directly reduces time-to-market for clinical pipelines while eliminating cross-border compliance risks. ARR expansion is further fueled by the monetisation of advanced automated data-processing modules powered by artificial intelligence.